var data={"title":"Diagnostic approach to the patient with polycythemia","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Diagnostic approach to the patient with polycythemia</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/contributors\" class=\"contributor contributor_credentials\">Ayalew Tefferi, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/contributors\" class=\"contributor contributor_credentials\">Stanley L Schrier, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/contributors\" class=\"contributor contributor_credentials\">Alan G Rosmarin, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Feb 15, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Polycythemia is a laboratory finding in which there is an increased number of red blood cells (RBC), along with an accompanying increase in the concentration of hemoglobin in the peripheral blood. The approach to the patient with polycythemia will be reviewed here. The approach to confirming a diagnosis of polycythemia vera is discussed separately. (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-polycythemia-vera\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of polycythemia vera&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">TERMINOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The red blood cell (RBC) count, hemoglobin (HGB), and hematocrit (HCT) are concentrations and therefore dependent upon the plasma volume as well as the total RBC mass (RCM). </p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">Relative polycythemia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>An isolated decrease in plasma volume can elevate the HGB, HCT, and RBC count without increasing the RCM; this is referred to as relative polycythemia. The state of chronically reduced plasma volume with elevated HGB or HCT has been called Gaisbock's disease, spurious polycythemia, stress erythrocytosis, apparent polycythemia, and pseudopolycythemia [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/1-4\" class=\"abstract_t\">1-4</a>], although many may be examples of smokers' polycythemia (see <a href=\"#H18\" class=\"local\">'Reduced plasma volume'</a> below)&nbsp;[<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/5\" class=\"abstract_t\">5</a>].</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Absolute polycythemia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In absolute polycythemia (also called erythrocytosis) there is an increased RCM. Patients are further categorized into primary and secondary forms (<a href=\"image.htm?imageKey=HEME%2F76036\" class=\"graphic graphic_table graphicRef76036 \">table 1</a>).</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h3\">Primary polycythemia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Primary polycythemia is caused by an acquired or inherited mutation leading to an abnormality within RBC progenitors; it includes polycythemia vera (PV) and rare familial variants (eg, activating mutations of the erythropoietin receptor, Chuvash polycythemia). (See <a href=\"topic.htm?path=molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera\" class=\"medical medical_review\">&quot;Molecular pathogenesis of congenital polycythemic disorders and polycythemia vera&quot;</a>.)</p><p>Idiopathic erythrocytosis has been used to categorize patients with primary polycythemia who do not fulfill conventional criteria for the diagnosis of PV [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/6\" class=\"abstract_t\">6</a>], including negativity for the exon 14 and exon 12 JAK2 mutations [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/7-9\" class=\"abstract_t\">7-9</a>]. (See <a href=\"topic.htm?path=overview-of-the-myeloproliferative-neoplasms#H13\" class=\"medical medical_review\">&quot;Overview of the myeloproliferative neoplasms&quot;, section on 'JAK2 mutations'</a>.)</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h3\">Secondary polycythemia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Secondary polycythemia is caused by a circulating factor stimulating erythropoiesis, usually erythropoietin (Epo). It is most often due to an Epo response to hypoxia, but can also result from an Epo-secreting tumor. (See <a href=\"topic.htm?path=molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera\" class=\"medical medical_review\">&quot;Molecular pathogenesis of congenital polycythemic disorders and polycythemia vera&quot;</a> and <a href=\"#H24\" class=\"local\">'Tumor polycythemia'</a> below.)</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h3\">Combined polycythemia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients may have an increased RCM as well as a reduced plasma volume, a combination most commonly seen in smokers (ie, &quot;smokers' polycythemia&quot;) [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/5\" class=\"abstract_t\">5</a>].</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h3\">Inapparent polycythemia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>If the RCM and plasma volume are equally increased, HGB, HCT, and RBC count remain normal [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/10\" class=\"abstract_t\">10</a>]. Polycythemia can only be detected via blood volume studies.</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h1\">PHYSIOLOGY OF ERYTHROPOIESIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Similar to all other blood cells, red blood cells (RBCs) are derived from the multipotent hematopoietic stem cell after a hierarchical process of lineage-commitment and differentiation. Under normal conditions, the earliest erythroid-committed progenitor cells depend on the trophic hormone erythropoietin (Epo) to further differentiate and produce RBCs. (See <a href=\"topic.htm?path=overview-of-hematopoietic-stem-cells\" class=\"medical medical_review\">&quot;Overview of hematopoietic stem cells&quot;</a>.)</p><p>Ninety percent of circulating Epo in humans is synthesized by the kidneys in response to a hypoxic signal. The hypoxic signal to the Epo-producing renal cells may be the result of reductions in hemoglobin (HGB) concentration (anemia) (<a href=\"image.htm?imageKey=HEME%2F53916\" class=\"graphic graphic_figure graphicRef53916 \">figure 1</a>), reduced hemoglobin oxygen saturation (hypoxemia), decreased oxygen release from hemoglobin (eg, high oxygen-affinity hemoglobinopathies), or reduced oxygen delivery to the kidney (eg, vascular occlusion). (See <a href=\"topic.htm?path=regulation-of-erythropoiesis#H19\" class=\"medical medical_review\">&quot;Regulation of erythropoiesis&quot;, section on 'Hypoxia-inducible factor and the response to hypoxia'</a>.)</p><p>A negative feedback inhibition mechanism downregulates Epo production with increasing oxygen delivery. Thus:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Epo-independent erythrocytosis (as in polycythemia vera) suppresses renal Epo production, resulting in low serum Epo concentrations [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/11-13\" class=\"abstract_t\">11-13</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Epo-driven erythropoiesis (eg, in hypoxia or with an Epo-secreting tumor) characterizes secondary erythrocytosis and is associated with normal or high serum Epo concentrations [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/13,14\" class=\"abstract_t\">13,14</a>].</p><p/><p class=\"headingAnchor\" id=\"H10\"><span class=\"h1\">INITIAL EVALUATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The major causes of polycythemia are listed in the table (<a href=\"image.htm?imageKey=HEME%2F76036\" class=\"graphic graphic_table graphicRef76036 \">table 1</a>). Several basic steps towards this evaluation are described below [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/15\" class=\"abstract_t\">15</a>]. At a minimum, the following should be obtained in all patients:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>History and physical examination</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pulse oximetry <span class=\"nowrap\">and/or</span> arterial oxygen saturation at rest and after exercise</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Complete blood count (CBC) with differential and red blood cell (RBC) indices</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Urinalysis</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Liver function studies</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Chest x-ray</p><p/><p>The CBC or other testing may be repeated if the results are discordant with the clinical presentation but repeat testing is not required.</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h2\">History</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>An accurate history is critical. The most common cause of polycythemia is hypoxia secondary to pulmonary disease; as a result, eliciting symptoms pertaining to altered lung function is of paramount importance. </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Symptoms due to the <strong>underlying polycythemia</strong> are related to the increased viscosity of blood (hyperviscosity) and may include any or all of the following: chest and abdominal pain, myalgia and weakness, fatigue, headache, blurred vision, transient loss of vision, paresthesias, slow mentation <span class=\"nowrap\">and/or</span> a sense of depersonalization [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/16\" class=\"abstract_t\">16</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Symptoms suggesting the presence of <strong>underlying pulmonary disease</strong> include shortness of breath, dyspnea on exertion, chronic cough, history of cyanosis, sleep-disordered breathing, and hypersomnolence with unintentional sleep.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Symptoms suggesting the diagnosis of <strong>polycythemia vera (PV)</strong> include pruritus after bathing, erythromelalgia, gout, arterial or venous thromboses, hemorrhage, and early satiety due to the presence of splenomegaly. (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-polycythemia-vera#H4\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of polycythemia vera&quot;, section on 'Clinical presentation'</a>.)</p><p/><p>Details of previously diagnosed heart <span class=\"nowrap\">and/or</span> lung conditions, as well as prior laboratory results should also be obtained. Other historical information may point directly to the etiology, such as living for extended periods of time at high altitude, patients previously placed on home oxygen therapy or respiratory assist devices, known intracardiac or intrapulmonary shunts, or renal transplantation. (See <a href=\"topic.htm?path=erythrocytosis-following-renal-transplantation\" class=\"medical medical_review\">&quot;Erythrocytosis following renal transplantation&quot;</a>.)</p><p>Since some polycythemic conditions can be inherited (eg, high oxygen affinity hemoglobinopathies), a family history of increased red blood cell (RBC) count, HGB, or HCT should be sought. (See <a href=\"topic.htm?path=genetic-disorders-of-hemoglobin-oxygen-affinity\" class=\"medical medical_review\">&quot;Genetic disorders of hemoglobin oxygen affinity&quot;</a>.)</p><p>Hereditary hemorrhagic telangiectasia, which can cause gastrointestinal bleeding and anemia, can also cause polycythemia secondary to the presence of pulmonary arteriovenous malformations. (See <a href=\"topic.htm?path=pulmonary-arteriovenous-malformations-epidemiology-etiology-and-pathology-in-adults#H177426874\" class=\"medical medical_review\">&quot;Pulmonary arteriovenous malformations: Epidemiology, etiology, and pathology in adults&quot;, section on 'Hereditary hemorrhagic telangiectasia (HHT)'</a> and <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome#H12\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)&quot;, section on 'Pulmonary AVMs'</a>.)</p><p>Medications and lifestyle activities can result in an increase in RBC mass (RCM). These include androgens (eg, testosterone) or anabolic steroids [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/17\" class=\"abstract_t\">17</a>], self-injection of erythropoietin, or transfusion of stored autologous or allogeneic RBC in order to improve athletic performance. (See <a href=\"topic.htm?path=testosterone-treatment-of-male-hypogonadism#H165681927\" class=\"medical medical_review\">&quot;Testosterone treatment of male hypogonadism&quot;, section on 'Erythrocytosis'</a> and <a href=\"topic.htm?path=use-of-androgens-and-other-hormones-by-athletes#H436157322\" class=\"medical medical_review\">&quot;Use of androgens and other hormones by athletes&quot;, section on 'Cardiovascular'</a>.)</p><p>A smoking history should be obtained, including the number of cigarettes (or cigars) smoked daily and whether or not the patient inhales the smoke. As noted above, polycythemia in association with plasma volume depletion can occur in smokers and in patients with marked volume depletion of any cause [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/5,18,19\" class=\"abstract_t\">5,18,19</a>]. (See <a href=\"topic.htm?path=etiology-clinical-manifestations-and-diagnosis-of-volume-depletion-in-adults\" class=\"medical medical_review\">&quot;Etiology, clinical manifestations, and diagnosis of volume depletion in adults&quot;</a> and <a href=\"topic.htm?path=clinical-assessment-and-diagnosis-of-hypovolemia-dehydration-in-children\" class=\"medical medical_review\">&quot;Clinical assessment and diagnosis of hypovolemia (dehydration) in children&quot;</a>.)</p><p>Chronic exposure to carbon monoxide (CO) should also be sought, especially in patients with recently detected polycythemia and symptoms such as headache, dizziness, nausea, malaise, and altered cognition. CO sources are often occupational, such as workers in underground parking lots or tunnels, taxi cab drivers working in congested environments, and workers in industries exposed to engine exhausts or products of combustion. It is reasonable to have the patient recount a typical workday in order to assess potentially toxic environments. This questioning can also include home situations, such as use of home heating devices and faulty venting of furnaces or fireplaces. (See <a href=\"topic.htm?path=carbon-monoxide-poisoning\" class=\"medical medical_review\">&quot;Carbon monoxide poisoning&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h2\">Physical examination</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In many medical centers, pulse oximetry for estimation of arterial oxygen saturation is considered a fifth vital sign; a low value suggests the presence of cardiopulmonary disease. Since some patients will not show reduced values for oxygen saturation while at rest or during the daytime, pulse oximetry should be obtained after minimal exertion and, if suggested by the clinical history, sleep studies may be necessary to determine the presence of nocturnal desaturation. (See <a href=\"topic.htm?path=overview-of-obstructive-sleep-apnea-in-adults\" class=\"medical medical_review\">&quot;Overview of obstructive sleep apnea in adults&quot;</a>.)</p><p>General examination of the patient includes observation for cyanosis in the lips, earlobes and fingers, and for clubbing in the nailbeds. The patient's breathing patterns should be noted, along with any obvious dyspnea or shortness of breath during the examination. The patient should also be examined for cardiac murmurs or bruits (as in pulmonary arteriovenous shunts and right to left cardiac shunts). (See <a href=\"topic.htm?path=auscultation-of-cardiac-murmurs-in-adults\" class=\"medical medical_review\">&quot;Auscultation of cardiac murmurs in adults&quot;</a>.) </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Abnormalities such as plethoric facies, dilated lingual or retinal veins, or areas of painful erythema may be seen in patients with PV.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Purple striae, ecchymoses, hirsutism, a buffalo hump, central obesity and moon facies suggest the diagnosis of Cushing's syndrome. (See <a href=\"topic.htm?path=epidemiology-and-clinical-manifestations-of-cushings-syndrome\" class=\"medical medical_review\">&quot;Epidemiology and clinical manifestations of Cushing's syndrome&quot;</a>.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Excessive sweating along with labile hypertension may be due to the presence of a pheochromocytoma. (See <a href=\"topic.htm?path=clinical-presentation-and-diagnosis-of-pheochromocytoma\" class=\"medical medical_review\">&quot;Clinical presentation and diagnosis of pheochromocytoma&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The presence of hepatomegaly and splenomegaly in a patient with polycythemia may reflect the presence of PV or an erythropoietin-secreting hepatoma [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/20,21\" class=\"abstract_t\">20,21</a>]. (See <a href=\"topic.htm?path=clinical-features-and-diagnosis-of-primary-hepatocellular-carcinoma\" class=\"medical medical_review\">&quot;Clinical features and diagnosis of primary hepatocellular carcinoma&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H13\"><span class=\"h2\">Laboratory testing</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Polycythemia is documented via an abnormality in one or more of the measures of red blood cell (RBC) number, including the RBC count, hemoglobin concentration (HGB), or hematocrit (HCT).</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>HCT </strong>&ndash; The HCT is expressed as the percent of a blood sample occupied by intact RBC. Polycythemia in the adult patient is considered to be present when the HCT is &gt;48 in women or &gt;49 percent in men.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>HGB </strong>&ndash; HGB is expressed in grams per 100 mL of whole blood or in grams per liter of whole blood. Polycythemia in the adult is considered to be present when the HGB is &gt;16.0 <span class=\"nowrap\">g/dL</span> (&gt;160 <span class=\"nowrap\">g/L)</span> in women or &gt;16.5 <span class=\"nowrap\">g/dL</span> (&gt;165 <span class=\"nowrap\">g/L)</span> in men.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>RBC count</strong> &ndash; The RBC count is expressed as the number of RBC per microL or liter of whole blood. The normal RBC count is approximately 5 x 10<sup>6 </sup>cells per microL or 5 x 10<sup>12</sup> cells per L. It is the least often used of the three tests to suggest polycythemia, since patients with thalassemia minor may have an elevated RBC count, but a reduced HCT or HGB due to the presence of an increased number of small (microcytic), poorly hemoglobinized (hypochromic) red cells.</p><p/><p>The following caveats and other findings on the CBC are worth consideration:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>It is imperative to apply the sex and age-adjusted &quot;normal&quot; reference intervals before considering polycythemia on the basis of HGB, HCT, or RBC count. The normal range in adults refers to the lower and upper limits observed in 95 percent of the normal population (<a href=\"image.htm?imageKey=HEME%2F64238\" class=\"graphic graphic_table graphicRef64238 \">table 2</a>). This does not necessarily imply that outlying values are always abnormal, since, by definition, 2.5 percent of the normal population will have values that exceed these 95 percent confidence limits. Normal values for children are strongly dependent on age and sex, and are given separately (<a href=\"image.htm?imageKey=PEDS%2F57465\" class=\"graphic graphic_table graphicRef57465 \">table 3</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A high RBC count along with a normal to reduced HGB and HCT and a reduced mean corpuscular volume (MCV) is a common finding in thalassemia minor. These individuals are not considered to have polycythemia since they do not have an accompanying increase in hemoglobin. (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-the-thalassemias#H1310990614\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of the thalassemias&quot;, section on 'CBC and routine laboratory studies'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>An elevated total white blood cell <span class=\"nowrap\">and/or</span> platelet count <span class=\"nowrap\">and/or</span> a reduced MCV should raise the suspicion of polycythemia vera. (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-polycythemia-vera\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of polycythemia vera&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Microscopic hematuria may be the only clue to the presence of an erythropoietin-secreting renal cell carcinoma [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/22\" class=\"abstract_t\">22</a>]. (See <a href=\"topic.htm?path=clinical-manifestations-evaluation-and-staging-of-renal-cell-carcinoma#H3\" class=\"medical medical_review\">&quot;Clinical manifestations, evaluation, and staging of renal cell carcinoma&quot;, section on 'Symptoms and signs'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Functioning endocrine tumors associated with polycythemia can produce hyperglycemia and electrolyte disturbances such as hypokalemia.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Abnormal liver function tests may suggest the presence of hepatocellular carcinoma, especially if the patient has a previous diagnosis of cirrhosis, viral hepatitis, or hemochromatosis. (See <a href=\"topic.htm?path=clinical-features-and-diagnosis-of-primary-hepatocellular-carcinoma#H4\" class=\"medical medical_review\">&quot;Clinical features and diagnosis of primary hepatocellular carcinoma&quot;, section on 'Paraneoplastic syndromes'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Most pulse oximeters are <strong>not </strong>sensitive to the presence of carbon monoxide (CO) and may give erroneous information in the presence of high levels of methemoglobin. As a result, direct blood testing via co-oximetry should be performed in all patients in whom CO poisoning or congenital methemoglobinemia is suspected as a cause of polycythemia. (See <a href=\"topic.htm?path=pulse-oximetry\" class=\"medical medical_review\">&quot;Pulse oximetry&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Chest x-ray &ndash; The chest x-ray may provide additional information concerning the genesis of the polycythemia (eg, arteriovenous malformations, chronic obstructive lung disease, pulmonary hypertension).</p><p/><p class=\"headingAnchor\" id=\"H15\"><span class=\"h1\">DOCUMENTATION AND DIAGNOSTIC APPROACH</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The following steps should be followed in order to document the presence of polycythemia and to determine its cause:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Polycythemia is considered to be present when the hematocrit (HCT) or hemoglobin (HGB) is elevated. We use values for HCT and HGB from the 2016 World Health Organization (WHO) classification of myeloid neoplasms [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/23\" class=\"abstract_t\">23</a>]:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>HCT &gt;48 percent in women or &gt;49 percent in men</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>HGB &gt;16.0 <span class=\"nowrap\">g/dL</span> in women or &gt;16.5 <span class=\"nowrap\">g/dL</span> in men</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The type of polycythemia (eg, relative, absolute, primary, secondary) can be determined via blood volume studies, if available, while the history and physical examination, simple laboratory testing (eg, complete blood count) and chest x-ray can often lead one to suspect its cause. (See <a href=\"#H10\" class=\"local\">'Initial evaluation'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pulse oximetry can determine if hypoxia is present at rest, following mild exercise, or during sleep, while measurement of serum erythropoietin (Epo) is helpful in determining whether the polycythemia is primary (eg, polycythemia vera with low Epo levels) or secondary (eg, cardiopulmonary disease, erythropoietin-secreting tumor with high Epo levels).</p><p/><p class=\"headingAnchor\" id=\"H16\"><span class=\"h2\">Blood volume measurement</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The classic method for documenting polycythemia is a blood volume study, using isotopic dilution methodology [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/24-27\" class=\"abstract_t\">24-27</a>], although non-radioactive labels (eg, carbon monoxide, <a href=\"topic.htm?path=biotin-vitamin-h-pediatric-drug-information\" class=\"drug drug_pediatric\">biotin</a>) have been used [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/28,29\" class=\"abstract_t\">28,29</a>]. Where testing is available, the red blood cell mass (RCM) is directly determined following infusion of the patient's own RBC labeled with a radioactive isotope (eg, Tc99m, Cr51), while the plasma volume is simultaneously and directly determined following infusion of isotopically-labeled human albumin.</p><p>While normal values differ according to age and sex, as well as from laboratory to laboratory, normal results are generally within the following ranges [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/5\" class=\"abstract_t\">5</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>RCM &ndash; 24 to 30 <span class=\"nowrap\">mL/kg</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Plasma volume &ndash; 39 to 49 <span class=\"nowrap\">mL/kg</span></p><p/><p>These methodologies have been standardized through the International Council for Standardization in Hematology (ICSH), with recommendations that volumes be normalized to body surface area (<a href=\"topic.htm?path=calculator-body-surface-area-mosteller-square-root-method\" class=\"calc calc_professional\">calculator 1</a>) rather than body weight or lean body weight, since the latter two methods are inaccurate in overweight patients [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/30\" class=\"abstract_t\">30</a>].</p><p>However, as a practical matter it has been the Mayo Clinic's experience that all female patients with a hemoglobin concentration above 16.5 <span class=\"nowrap\">g/dL</span> and all male patients with HGB concentration above 18.5 <span class=\"nowrap\">g/dL</span> (or HCT greater than 50 and 56 percent, respectively) have an increased RCM. Somewhat different values were obtained in a report from Belgium in which HCT above 55 and 60 percent in women and men, respectively, were associated with an increase in RCM [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/31\" class=\"abstract_t\">31</a>]. Thus, the expense of a directly-measured RCM may not be justified for this group of patients.</p><p class=\"headingAnchor\" id=\"H17\"><span class=\"h2\">Blood volume estimation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>It is possible to measure either the RCM or the plasma volume and to estimate the other from the HCT of a blood sample taken from a peripheral vein. However, total body HCT (defined as RCM &divide; [RCM + plasma volume]) is usually 8 to 11 percent lower than the HCT obtained from large peripheral vessels [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/32\" class=\"abstract_t\">32</a>]. Because of this error, use of the indirect method is not recommended for diagnostic purposes [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/33\" class=\"abstract_t\">33</a>].</p><p>Although directly measured values for RCM and plasma volume are accurate and constitute the &quot;gold standard&quot; [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/34\" class=\"abstract_t\">34</a>], an evidence-based critical review has raised several clinically relevant issues [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/26\" class=\"abstract_t\">26</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Blood volume measurements using isotope dilution are costly, time consuming, and no longer available in many locations.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>There is an excellent correlation between RCM and HCT; the additional information obtained from blood volume studies may not be critical.</p><p/><p>As an example, it has been the Mayo Clinic's experience that all female patients with a hemoglobin concentration above 16.5 <span class=\"nowrap\">g/dL</span> and all male patients with HGB concentration above 18.5 <span class=\"nowrap\">g/dL</span> (or HCT greater than 50 and 56 percent, respectively) have an increased RCM. Somewhat different values were obtained in a report from Belgium in which HCT above 55 and 60 percent in women and men, respectively, were associated with an increase in RCM [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/31\" class=\"abstract_t\">31</a>]. Thus, the expense of a directly-measured RCM may not be justified for this group of patients.</p><p class=\"headingAnchor\" id=\"H18\"><span class=\"h2\">Reduced plasma volume</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>It might be argued that RCM and plasma volume measurements at lower HGB values (&lt;16.0 <span class=\"nowrap\">g/dL</span> in women and &lt;16.5 <span class=\"nowrap\">g/dL</span> in men) are needed in order to distinguish absolute polycythemia from relative or inapparent polycythemia [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/10\" class=\"abstract_t\">10</a>]. However, some studies have questioned the existence of relative polycythemia as a separate nosologic entity [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/3,26\" class=\"abstract_t\">3,26</a>]. The original studies regarding relative polycythemia had the following problems [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/4\" class=\"abstract_t\">4</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>They included patients with high normal HCT values.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The observations were based on plasma volume estimates indirectly derived from RCM measurements.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The observed values were not corrected for lean body mass or for the difference between venous and whole body HCT values.</p><p/><p>In studies performed at the Mayo Clinic, only 7 of 40 patients with relative polycythemia were found to have reduced plasma volumes when both RCM and plasma volumes were measured independently and the measurements were calculated on the basis of ideal body weight [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/35\" class=\"abstract_t\">35</a>]. In a later evaluation of 119 consecutive RCM and plasma volume measurements at the Mayo Clinic, not a single case of relative polycythemia was encountered [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/26\" class=\"abstract_t\">26</a>]. However, this position is not universally held [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/36,37\" class=\"abstract_t\">36,37</a>]. (See <a href=\"topic.htm?path=etiology-clinical-manifestations-and-diagnosis-of-volume-depletion-in-adults#H29\" class=\"medical medical_review\">&quot;Etiology, clinical manifestations, and diagnosis of volume depletion in adults&quot;, section on 'Hematocrit and serum albumin concentration'</a>.)</p><p>One setting in which reduced plasma volume may be important is in polycythemic smokers. Studies in such patients have found a combination of an increased RCM and a reduced plasma volume in the majority [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/5,18\" class=\"abstract_t\">5,18</a>]. These abnormalities return to normal with cessation of smoking.</p><p>Extracellular fluid volume depletion of any cause can produce relative polycythemia that is readily reversed with fluid repletion, or by removal of the offending agent (eg, smoking of tobacco, use of caffeine-containing beverages, diuretics) [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/38\" class=\"abstract_t\">38</a>].</p><p class=\"headingAnchor\" id=\"H19\"><span class=\"h1\">FURTHER EVALUATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Following the initial evaluation, the clinician should be able to rule in or out a number of conditions associated with polycythemia. If repeat blood counts have been performed and are normal, and if no suspicious findings have been uncovered, no further investigation is necessary.</p><p>If the initial evaluation indicates polycythemia, the following guidelines will help in determining the next diagnostic steps:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>If exposure to tobacco smoke, engine exhaust, or other sources of carbon monoxide is a possibility, a blood carboxyhemoglobin (COHGB) determination should be performed. If exposures are related to smoking or the subject's occupation, the sampling should be performed at the end of the day, when levels will be at their highest. If exposure to carbon monoxide (CO) is in the home, sampling should be performed as soon as possible after arising in the morning.</p><p/><p class=\"bulletIndent1\">COHGB values in excess of 5 percent strongly suggest polycythemia secondary to CO poisoning. This diagnosis is confirmed only if CO exposures can be stopped, with subsequent return of blood values to normal over the ensuing two to three months [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/5,18\" class=\"abstract_t\">5,18</a>]. A clue to the presence of smoking-related polycythemia is prompt reversal of a low plasma volume following cessation of smoking [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/5\" class=\"abstract_t\">5</a>]. This is manifested clinically by a reduction in hematocrit (HCT) of four or more percentage points within a few days of stopping smoking. Phlebotomy is not indicated in these patients unless the patient is symptomatic and the total blood volume of the patient is increased.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>If hypoxia is a clinical possibility, screening with pulse oximetry should be performed. If this is not available, arterial oxygen saturation should be measured with the patient at rest, after minimal exercise, or during sleep, depending upon the clinical situation. (See <a href=\"topic.htm?path=pulse-oximetry\" class=\"medical medical_review\">&quot;Pulse oximetry&quot;</a>.)</p><p/><p>When the cause of polycythemia is not clear, and especially when arterial oxygen tension (pO2) is normal, <strong>direct measurement</strong> of arterial hemoglobin oxygen saturation should be performed. A low saturation in the presence of normal arterial oxygen tension suggests the presence of high concentrations of carboxyhemoglobin or methemoglobin, which can be confirmed via co-oximetry. (See <a href=\"topic.htm?path=clinical-features-diagnosis-and-treatment-of-methemoglobinemia#H17\" class=\"medical medical_review\">&quot;Clinical features, diagnosis, and treatment of methemoglobinemia&quot;, section on 'Diagnosis'</a>.)</p><p>The presence of a high oxygen affinity hemoglobin may be suggested by a positive family history of polycythemia, and is confirmed by showing a &quot;left-shifted&quot; hemoglobin oxygen dissociation curve, characterized by a reduced P<sub>50</sub> (ie, the oxygen partial pressure at which hemoglobin is 50 percent saturated with oxygen) (<a href=\"image.htm?imageKey=HEME%2F81216\" class=\"graphic graphic_figure graphicRef81216 \">figure 2</a>). Indirect calculation of the arterial oxygen saturation from the arterial oxygen tension alone will miss these disorders. (See <a href=\"topic.htm?path=genetic-disorders-of-hemoglobin-oxygen-affinity\" class=\"medical medical_review\">&quot;Genetic disorders of hemoglobin oxygen affinity&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A combined blood volume study may be ordered to determine whether polycythemia is due to an elevation in red blood cell mass (RCM), a reduction in plasma volume, or both (see <a href=\"#H16\" class=\"local\">'Blood volume measurement'</a> above). However, a venous HCT significantly in excess of 56 to 60 percent in men and 50 to 55 percent in women is almost always associated with an absolute increase in RCM [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/31\" class=\"abstract_t\">31</a>]. (See <a href=\"#H17\" class=\"local\">'Blood volume estimation'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In all other cases, it is reasonable to start the investigation by measuring the serum erythropoietin (Epo) concentration.</p><p/><p class=\"headingAnchor\" id=\"H20\"><span class=\"h2\">Serum erythropoietin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A low serum erythropoietin (Epo) level in the patient with erythrocytosis is relatively specific for the diagnosis of polycythemia vera (PV), although it can also be seen in the rare cases of congenital erythrocytosis characterized by an activating mutation in the erythropoietin receptor (called primary familial and congenital polycythemia) [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/39-41\" class=\"abstract_t\">39-41</a>]. Low serum Epo may also be seen in &quot;blood doping&quot; (autologous transfusion). If PV is strongly suspected and the initial value for Epo is normal, repeat testing may reveal a reduced value. Confirmation of the diagnosis of PV can then be made via methods outlined elsewhere (<a href=\"image.htm?imageKey=HEME%2F102385\" class=\"graphic graphic_algorithm graphicRef102385 \">algorithm 1</a>). (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-polycythemia-vera\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of polycythemia vera&quot;</a>.)</p><p>Erythrocytosis associated with increased serum Epo is unlikely to represent PV [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/13,14,42\" class=\"abstract_t\">13,14,42</a>], and a working diagnosis of secondary erythrocytosis should be made [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/11,13\" class=\"abstract_t\">11,13</a>].</p><p class=\"headingAnchor\" id=\"H10215468\"><span class=\"h2\">JAK2 mutation testing</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Testing for the JAK2 mutation is essential if the diagnosis of PV is being considered, as virtually all patients will have a mutation in either exon 12 or 14 of this gene. It is a major criterion for this diagnosis (<a href=\"image.htm?imageKey=HEME%2F110224\" class=\"graphic graphic_table graphicRef110224 \">table 4</a>). (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-polycythemia-vera#H3008612693\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of polycythemia vera&quot;, section on 'JAK2 mutations'</a>.) </p><p class=\"headingAnchor\" id=\"H2597591\"><span class=\"h2\">Bone marrow aspiration and biopsy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A bone marrow <span class=\"nowrap\">aspirate/biopsy</span> is not generally required as part of the workup for polycythemia vera (PV), but may be useful if a PV-related complication is being considered (eg, myelofibrosis, myelodysplasia, myeloid leukemia). Otherwise, bone marrow aspiration and biopsy is not required for the evaluation of patients with polycythemia. (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-polycythemia-vera#H926361313\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of polycythemia vera&quot;, section on 'Bone marrow aspiration and biopsy'</a>.)</p><p class=\"headingAnchor\" id=\"H21\"><span class=\"h1\">EVALUATION OF SECONDARY ERYTHROCYTOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Secondary erythrocytosis can be either congenital [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/43\" class=\"abstract_t\">43</a>] or acquired (<a href=\"image.htm?imageKey=HEME%2F76036\" class=\"graphic graphic_table graphicRef76036 \">table 1</a>)&nbsp;[<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/44\" class=\"abstract_t\">44</a>]. In both situations, the increase in serum erythropoietin (Epo) level may represent an &quot;appropriate&quot; response to generalized hypoxia, as in chronic obstructive lung disease or a high oxygen affinity hemoglobinopathy. In some of these patients, serum Epo is normal because the appropriate Epo response is feedback-sensitive to the subsequent elevation in oxygen-carrying capacity.</p><p>On the other hand, erythrocytosis associated with tumors or renal vascular disease is usually associated with significantly elevated serum Epo, since areas of hypoxic kidney and Epo-secreting tumors are not generally feedback sensitive to the increased oxygen carrying capacity generated by an elevated red blood cell mass (RCM) (see <a href=\"#H24\" class=\"local\">'Tumor polycythemia'</a> below).</p><p class=\"headingAnchor\" id=\"H22\"><span class=\"h2\">Congenital polycythemia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Congenital polycythemia is suspected when the onset of polycythemia is at an early age or there is a positive family history of polycythemia. Mutant high-affinity hemoglobins have abnormal migration on starch gel electrophoresis in about 50 percent of cases. However, laboratory investigation usually begins with the determination of the oxygen pressure at 50 percent hemoglobin saturation (P<sub>50</sub>) (<a href=\"image.htm?imageKey=HEME%2F81216\" class=\"graphic graphic_figure graphicRef81216 \">figure 2</a>). A low P<sub>50</sub> suggests either a high oxygen affinity hemoglobinopathy (autosomal dominant) or familial 2,3-bisphosphoglycerate (2,3-BPG) deficiency (autosomal recessive). Serum erythropoietin (Epo) is usually normal in both of these disorders because of the negative feedback inhibition of Epo by the erythrocytosis. (See <a href=\"topic.htm?path=genetic-disorders-of-hemoglobin-oxygen-affinity\" class=\"medical medical_review\">&quot;Genetic disorders of hemoglobin oxygen affinity&quot;</a>.)</p><p>A normal P<sub>50</sub> in a patient with a familial erythrocytosis is consistent with either autosomal dominant (benign) familial erythrocytosis (BFE) or autosomal recessive familial erythrocytosis (RFE) [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/43\" class=\"abstract_t\">43</a>]. (See <a href=\"topic.htm?path=molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera\" class=\"medical medical_review\">&quot;Molecular pathogenesis of congenital polycythemic disorders and polycythemia vera&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>BFE is usually associated with low or normal Epo and erythroid progenitor Epo-hypersensitivity [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/45\" class=\"abstract_t\">45</a>]. Activating EPO receptor mutations have been recognized in many of these patients, a disorder also called primary familial and congenital polycythemia [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/39-41\" class=\"abstract_t\">39-41</a>]. However, some patients with autosomal dominant disease have autonomous overproduction of Epo and elevated serum Epo [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/46\" class=\"abstract_t\">46</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>RFE is the most frequent form of familial erythrocytosis and is prevalent in Russia (Chuvash polycythemia). Epo levels in RFE are variable.</p><p/><p>Congenital cyanotic heart disease can also cause secondary polycythemia. (See <a href=\"topic.htm?path=overview-of-cyanosis-in-the-newborn\" class=\"medical medical_review\">&quot;Overview of cyanosis in the newborn&quot;</a> and <a href=\"topic.htm?path=approach-to-cyanosis-in-children\" class=\"medical medical_review\">&quot;Approach to cyanosis in children&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H23\"><span class=\"h2\">Acquired secondary polycythemia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Acquired secondary erythrocytosis is an erythropoietin (Epo)-driven process initiated by either an oxygen-sensitive Epo response to hypoxia or an unregulated pathologic production of Epo by tumors (<a href=\"image.htm?imageKey=HEME%2F76036\" class=\"graphic graphic_table graphicRef76036 \">table 1</a>). (See <a href=\"topic.htm?path=oxygenation-and-mechanisms-of-hypoxemia\" class=\"medical medical_review\">&quot;Oxygenation and mechanisms of hypoxemia&quot;</a>.)</p><p>An oxygen-sensitive Epo response is further classified as being &quot;appropriate&quot; or &quot;inappropriate&quot; depending upon whether the hypoxic stimulus is generalized or regional. The degree of EPO elevation may differ among the various conditions associated with secondary erythrocytosis. In general, serum EPO concentrations are highest in congenital heart disease with right-to-left shunting or following renal transplantation [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/47\" class=\"abstract_t\">47</a>]. (See <a href=\"topic.htm?path=medical-management-of-cyanotic-congenital-heart-disease-in-adults#H4\" class=\"medical medical_review\">&quot;Medical management of cyanotic congenital heart disease in adults&quot;, section on 'Erythrocytosis and relative anemia'</a> and <a href=\"topic.htm?path=erythrocytosis-following-renal-transplantation\" class=\"medical medical_review\">&quot;Erythrocytosis following renal transplantation&quot;</a>.)</p><p>However, some patients with post-transplant erythrocytosis do not have elevated serum Epo. Non-Epo factors in this setting may either enhance the sensitivity to Epo or directly promote erythropoiesis [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/47\" class=\"abstract_t\">47</a>]. Implicated proteins include insulin-like growth factor-1 and insulin-like growth factor binding proteins, growth factors known to enhance erythropoiesis [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/48\" class=\"abstract_t\">48</a>]. Regardless of the mechanism, post-transplant erythrocytosis generally responds to the administration of an angiotensin converting enzyme inhibitor or receptor antagonist.</p><p>If arterial oxygen tension, hemoglobin oxygen saturation, and carboxyhemoglobin levels are normal, further investigation depends upon the particular clinical situation and the degree of Epo elevation. An otherwise unexplained erythrocytosis associated with increased serum Epo may require performance of an abdominal ultrasound or renal vascular studies to rule out renal artery stenosis [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/49-51\" class=\"abstract_t\">49-51</a>], or other imaging procedures (eg, abdominal CT scan) to rule out the presence of an Epo-secreting tumor [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/21,22\" class=\"abstract_t\">21,22</a>].</p><p class=\"headingAnchor\" id=\"H24\"><span class=\"h3\">Tumor polycythemia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The five tumors most commonly associated with the overproduction of erythropoietin (ie, paraneoplastic erythrocytosis) are hepatocellular carcinoma, renal cell carcinoma, hemangioblastoma , pheochromocytoma [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/52\" class=\"abstract_t\">52</a>], and uterine myomata. An abdominal CT scan, including the uterus in polycythemic females should be sufficient for diagnosing tumors at these locations in subjects who are polycythemic with normal arterial oxygen studies and increased erythropoietin levels. CT or MRI of the brain will be needed if a hemangioblastoma is suspected.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Raised serum Epo is present in up to 23 percent of patients with hepatocellular carcinoma [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/21\" class=\"abstract_t\">21</a>]. However, the incidence of elevated serum Epo is higher than the incidence of erythrocytosis, presumably due to the inhibition of erythropoiesis by the malignancy as well as bleeding associated with esophageal varices <span class=\"nowrap\">and/or</span> a coagulopathy due to reduced hepatic production of clotting factors. (See <a href=\"topic.htm?path=clinical-features-and-diagnosis-of-primary-hepatocellular-carcinoma#H6\" class=\"medical medical_review\">&quot;Clinical features and diagnosis of primary hepatocellular carcinoma&quot;, section on 'Erythrocytosis'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Erythrocytosis occurs in 1 to 5 percent of patients with renal cell carcinoma and appears to be due to the constitutive production of erythropoietin&nbsp;[<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/22\" class=\"abstract_t\">22</a>]. (See <a href=\"topic.htm?path=clinical-manifestations-evaluation-and-staging-of-renal-cell-carcinoma#H10\" class=\"medical medical_review\">&quot;Clinical manifestations, evaluation, and staging of renal cell carcinoma&quot;, section on 'Erythrocytosis'</a>.) </p><p/><p class=\"bulletIndent1\">Hemangioblastomas are slow-growing tumors of the central nervous system and may occur sporadically or as a manifestation of von Hippel-Lindau disease. Paraneoplastic polycythemia has been reported in these patients as a result of excessive erythropoietin production by the tumor. (See <a href=\"topic.htm?path=hemangioblastoma#H4\" class=\"medical medical_review\">&quot;Hemangioblastoma&quot;, section on 'Symptoms'</a>.)<br/><br/>Since the mutated von Hippel-Lindau gene, which is present is many of these tumors, impairs the regulation of hypoxia-induced proteins [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/53,54\" class=\"abstract_t\">53,54</a>], erythrocytosis may be directly related to impaired sensing of the ambient oxygen tension. (See <a href=\"topic.htm?path=regulation-of-erythropoiesis\" class=\"medical medical_review\">&quot;Regulation of erythropoiesis&quot;</a> and <a href=\"topic.htm?path=molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera#H9\" class=\"medical medical_review\">&quot;Molecular pathogenesis of congenital polycythemic disorders and polycythemia vera&quot;, section on 'Chuvash polycythemia'</a> and <a href=\"topic.htm?path=molecular-biology-and-pathogenesis-of-von-hippel-lindau-disease#H3\" class=\"medical medical_review\">&quot;Molecular biology and pathogenesis of von Hippel-Lindau disease&quot;, section on 'Hypoxia-inducible factor 1 and 2'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Uterine myomata (fibroids) have been associated with secondary erythrocytosis, normal to increased serum Epo levels, immunologic evidence for Epo production by the leiomyoma cells, and reversal of erythrocytosis following myomectomy [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/55,56\" class=\"abstract_t\">55,56</a>]. A clue to the presence of the myomatous erythrocytosis syndrome is the absence of anemia in a patient with significant menorrhagia [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/57\" class=\"abstract_t\">57</a>]. (See <a href=\"topic.htm?path=uterine-leiomyomas-fibroids-epidemiology-clinical-features-diagnosis-and-natural-history\" class=\"medical medical_review\">&quot;Uterine leiomyomas (fibroids): Epidemiology, clinical features, diagnosis, and natural history&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H25\"><span class=\"h2\">Management</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Management of secondary erythrocytosis is twofold:</p><p class=\"headingAnchor\" id=\"H4659894\"><span class=\"h3\">Removal of the underlying cause</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Removal of the underlying cause, if possible, is the most direct approach (eg, excision of an erythropoietin-secreting tumor, cessation of exposure to carbon monoxide, stopping treatment with testosterone or an anabolic steroid, closure of a right-to-left shunt) [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/56,58\" class=\"abstract_t\">56,58</a>]. (See <a href=\"topic.htm?path=therapeutic-approach-to-adult-patients-with-pulmonary-arteriovenous-malformations#H706913647\" class=\"medical medical_review\">&quot;Therapeutic approach to adult patients with pulmonary arteriovenous malformations&quot;, section on 'Patients suitable for embolotherapy'</a>.)</p><p class=\"headingAnchor\" id=\"H4659900\"><span class=\"h3\">Limited phlebotomy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Limited phlebotomy is appropriate in the presence of symptoms of an increased blood volume <span class=\"nowrap\">and/or</span> hyperviscosity [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/59-62\" class=\"abstract_t\">59-62</a>]. Such patients may achieve relief following a modest reduction in their hematocrit, but may become more symptomatic if the hematocrit is reduced to the normal range. </p><p>As an example, individuals with secondary erythrocytosis due to a response to chronic hypoxia (eg, right-to-left cardiac shunt, chronic pulmonary disease) may have symptoms of an increased blood <span class=\"nowrap\">volume/hyperviscosity</span> (eg, fatigue, headache, blurred vision, transient loss of vision, paresthesias, slow mentation) when their hematocrit rises to 65 percent or more. Cautious phlebotomy to reduce their hematocrit into the range of approximately 55 to 60 percent may result in relief of these symptoms, while a reduction in their hematocrit to levels less than 55 percent range are likely to exacerbate symptoms of their underlying hypoxic condition (eg, shortness of breath, dyspnea on exertion).</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Because such phlebotomies may be poorly tolerated, the first phlebotomy should be limited in volume (eg, 250 mL rather than the standard 500 mL) and performed as isovolemic phlebotomy (ie, replacement of removed blood with an equal volume of crystalloid) [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/15,16\" class=\"abstract_t\">15,16</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Phlebotomy may be poorly tolerated, if at all, in those with a high hematocrit due to a reduced plasma volume (eg, relative polycythemia). In such individuals, routine phlebotomy may result in cardiovascular compromise (eg, dizziness on standing, hypotension) due to a further reduction in blood volume.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The management of individuals with cyanotic congenital heart disease with respect to management of an increased hematocrit is discussed in detail separately. (See <a href=\"topic.htm?path=management-of-eisenmenger-syndrome#H18\" class=\"medical medical_review\">&quot;Management of Eisenmenger syndrome&quot;, section on 'Noncardiac surgery'</a> and <a href=\"topic.htm?path=medical-management-of-cyanotic-congenital-heart-disease-in-adults#H4\" class=\"medical medical_review\">&quot;Medical management of cyanotic congenital heart disease in adults&quot;, section on 'Erythrocytosis and relative anemia'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H26\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Polycythemia is a laboratory finding in which there is an increased number of red blood cells (RBC), with an accompanying increase in hematocrit and the concentration of hemoglobin in the peripheral blood. It is most commonly due to an appropriate response of the bone marrow to chronic hypoxia, use of androgens or anabolic steroids, an erythropoietin-secreting tumor, or to germline or somatic mutations altering the sensing of hypoxia <span class=\"nowrap\">and/or</span> the production of erythropoietin (<a href=\"image.htm?imageKey=HEME%2F76036\" class=\"graphic graphic_table graphicRef76036 \">table 1</a>).</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Suspecting the diagnosis</strong> &ndash; Polycythemia is suspected in a number of different clinical settings, including living at high altitude, use of certain drugs, cyanosis-associated cardiac or pulmonary disease, tumors known to secrete erythropoietin, and a number of genetic and acquired disorders. Accordingly, an extensive history and physical examination is required to evaluate for these possibilities. (See <a href=\"#H10\" class=\"local\">'Initial evaluation'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Diagnosing polycythemia</strong> &ndash; A diagnosis of absolute polycythemia (ie, polycythemia due to an increase in circulating red cells, hemoglobin, and hematocrit) depends upon whether or not a blood volume study has been performed:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>If a blood volume study has been performed, absolute polycythemia is present when the measured red blood cell mass exceeds 30 <span class=\"nowrap\">mL/kg</span> body weight. (See <a href=\"#H16\" class=\"local\">'Blood volume measurement'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>If a blood volume study cannot be performed or is unavailable, absolute polycythemia is considered to be present when the hematocrit is &gt;48 percent in women or &gt;49 percent in men, or when the hemoglobin concentration is &gt;16.0 <span class=\"nowrap\">g/dL</span> in women or &gt;16.5 <span class=\"nowrap\">g/dL</span> in men. (See <a href=\"#H17\" class=\"local\">'Blood volume estimation'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>An accurate history and physical examination is critical in order to determine the etiology of polycythemia (<a href=\"image.htm?imageKey=HEME%2F76036\" class=\"graphic graphic_table graphicRef76036 \">table 1</a>). The most common cause of polycythemia is hypoxia secondary to pulmonary disease; as a result, eliciting symptoms pertaining to altered lung function is of paramount importance. (See <a href=\"#H10\" class=\"local\">'Initial evaluation'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A low value for oxygen saturation on pulse oximetry or arterial puncture suggests the presence of cardiopulmonary disease (eg, chronic obstructive pulmonary disease, pulmonary A-V malformations, right to left cardiac shunt). Such studies should be obtained after minimal exertion and, if suggested by the clinical history, sleep studies may be necessary to detect nocturnal oxygen unsaturation.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A low serum erythropoietin (Epo) level in the polycythemic patient suggests the diagnosis of polycythemia vera (PV) (<a href=\"image.htm?imageKey=HEME%2F102385\" class=\"graphic graphic_algorithm graphicRef102385 \">algorithm 1</a>). Polycythemia associated with increased serum Epo is unlikely to represent PV and a working diagnosis of secondary erythrocytosis should be made. (See <a href=\"#H21\" class=\"local\">'Evaluation of secondary erythrocytosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>If PV is a diagnostic consideration, other testing, such as for the JAK2 mutation, is indicated. (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-polycythemia-vera#H32\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of polycythemia vera&quot;, section on 'Summary and recommendations'</a>.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/1\" class=\"nounderline abstract_t\">LAWRENCE JH, BERLIN NI. Relative polycythemia; the polycythemia of stress. Yale J Biol Med 1952; 24:498.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/2\" class=\"nounderline abstract_t\">Berlin NI, Wasserman LR. Polycythemia vera: a retrospective and reprise. J Lab Clin Med 1997; 130:365.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/3\" class=\"nounderline abstract_t\">Brown SM, Gilbert HS, Krauss S, Wasserman LR. Spurious (relative) polycythemia: a nonexistent disease. Am J Med 1971; 50:200.</a></li><li class=\"breakAll\">Weinreb NJ. Relative polycythemia. In: Polycythemia Vera and the Myeloproliferative Disorders, Wasserman LR, Berk PD, Berlin NI (Eds), WB Saunders, Philadelphia 1995. p.226.</li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/5\" class=\"nounderline abstract_t\">Smith JR, Landaw SA. Smokers' polycythemia. N Engl J Med 1978; 298:6.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/6\" class=\"nounderline abstract_t\">Messinezy M, Sawyer B, Westwood NB, Pearson TC. Idiopathic erythrocytosis--additional new study techniques suggest a heterogenous group. Eur J Haematol 1994; 53:163.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/7\" class=\"nounderline abstract_t\">Rossi D, Cortini F, Deambrogi C, et al. Usefulness of JAK2V617F mutation in distinguishing idiopathic erythrocytosis from polycythemia vera. Leuk Res 2007; 31:97.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/8\" class=\"nounderline abstract_t\">Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007; 356:459.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/9\" class=\"nounderline abstract_t\">Tefferi A. JAK2 mutations in polycythemia vera--molecular mechanisms and clinical applications. N Engl J Med 2007; 356:444.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/10\" class=\"nounderline abstract_t\">Lamy T, Devillers A, Bernard M, et al. Inapparent polycythemia vera: an unrecognized diagnosis. Am J Med 1997; 102:14.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/11\" class=\"nounderline abstract_t\">Birgeg&aring;rd G, Wide L. Serum erythropoietin in the diagnosis of polycythaemia and after phlebotomy treatment. Br J Haematol 1992; 81:603.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/12\" class=\"nounderline abstract_t\">Weinberg RS. In vitro erythropoiesis in polycythemia vera and other myeloproliferative disorders. Semin Hematol 1997; 34:64.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/13\" class=\"nounderline abstract_t\">Najean Y, Schlageter MH, Toubert ME, Podgorniak MP. Radioimmunoassay of immunoreactive erythropoietin as a clinical tool for the classification of polycythaemias. Nouv Rev Fr Hematol 1990; 32:237.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/14\" class=\"nounderline abstract_t\">Remacha AF, Montserrat I, Santamaria A, et al. Serum erythropoietin in the diagnosis of polycythemia vera. A follow-up study. Haematologica 1997; 82:406.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/15\" class=\"nounderline abstract_t\">McMullin MF, Bareford D, Campbell P, et al. Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. Br J Haematol 2005; 130:174.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/16\" class=\"nounderline abstract_t\">Keohane C, McMullin MF, Harrison C. The diagnosis and management of erythrocytosis. BMJ 2013; 347:f6667.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/17\" class=\"nounderline abstract_t\">Krauss DJ, Taub HA, Lantinga LJ, et al. Risks of blood volume changes in hypogonadal men treated with testosterone enanthate for erectile impotence. J Urol 1991; 146:1566.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/18\" class=\"nounderline abstract_t\">Aitchison R, Russell N. Smoking--a major cause of polycythaemia. J R Soc Med 1988; 81:89.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/19\" class=\"nounderline abstract_t\">Pollak R, Maddux MS, Cohan J, et al. Erythrocythemia following renal transplantation: influence of diuretic therapy. Clin Nephrol 1988; 29:119.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/20\" class=\"nounderline abstract_t\">Sakisaka S, Watanabe M, Tateishi H, et al. Erythropoietin production in hepatocellular carcinoma cells associated with polycythemia: immunohistochemical evidence. Hepatology 1993; 18:1357.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/21\" class=\"nounderline abstract_t\">Kew MC, Fisher JW. Serum erythropoietin concentrations in patients with hepatocellular carcinoma. Cancer 1986; 58:2485.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/22\" class=\"nounderline abstract_t\">Da Silva JL, Lacombe C, Bruneval P, et al. Tumor cells are the site of erythropoietin synthesis in human renal cancers associated with polycythemia. Blood 1990; 75:577.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/23\" class=\"nounderline abstract_t\">Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127:2391.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/24\" class=\"nounderline abstract_t\">Pearson TC, Messinezy M. Investigation of patients with polycythaemia. Postgrad Med J 1996; 72:519.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/25\" class=\"nounderline abstract_t\">Bernard PJ. Measurement of red-cell and plasma volumes. Nouv Rev Fr Hematol 1994; 36:155.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/26\" class=\"nounderline abstract_t\">Fairbanks VF, Klee GG, Wiseman GA, et al. Measurement of blood volume and red cell mass: re-examination of 51Cr and 125I methods. Blood Cells Mol Dis 1996; 22:169.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/27\" class=\"nounderline abstract_t\">Holme S, Elfath MD, Heaton A, et al. Prediction of red cell and blood volumes distribution by various nomograms: do current nomograms overestimate? Transfusion 2008; 48:910.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/28\" class=\"nounderline abstract_t\">Schmidt W, Prommer N. The optimised CO-rebreathing method: a new tool to determine total haemoglobin mass routinely. Eur J Appl Physiol 2005; 95:486.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/29\" class=\"nounderline abstract_t\">Mock DM, Matthews NI, Strauss RG, et al. Red blood cell volume can be independently determined in vitro using sheep and human red blood cells labeled at different densities of biotin. Transfusion 2009; 49:1178.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/30\" class=\"nounderline abstract_t\">Pearson TC, Guthrie DL, Simpson J, et al. Interpretation of measured red cell mass and plasma volume in adults: Expert Panel on Radionuclides of the International Council for Standardization in Haematology. Br J Haematol 1995; 89:748.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/31\" class=\"nounderline abstract_t\">Ferrant A. What clinical and laboratory data are indicative of polycythemia and when are blood volume studies needed? Nouv Rev Fr Hematol 1994; 36:151.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/32\" class=\"nounderline abstract_t\">BUTTON LN, GIBSON JG 2nd, WALTER CW. SIMULTANEOUS DETERMINATION OF THE VOLUME OF RED CELLS AND PLASMA FOR SURVIVAL STUDIES OF STORED BLOOD. Transfusion 1965; 5:143.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/33\" class=\"nounderline abstract_t\">Nielsen S, R&oslash;dbro P. Validity of rapid estimation of erythrocyte volume in the diagnosis of polycytemia vera. Eur J Nucl Med 1989; 15:32.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/34\" class=\"nounderline abstract_t\">Spivak JL. The optimal management of polycythaemia vera. Br J Haematol 2002; 116:243.</a></li><li class=\"breakAll\">Fairbanks VF, Tauxe WN. Plasma and erythrocyte volumes in obesity, polycythemia, and related conditions. In: , Pools and Spaces in Medical Physiology, USAEC Division of Technical Information, Oak Ridge, TN 1967. p.283.</li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/36\" class=\"nounderline abstract_t\">Spivak JL. Polycythemia vera: myths, mechanisms, and management. Blood 2002; 100:4272.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/37\" class=\"nounderline abstract_t\">Silver RT, Chow W, Orazi A, et al. Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis. Blood 2013; 122:1881.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/38\" class=\"nounderline abstract_t\">Landaw SA. Polycythemia vera and other polycythemic states. Clin Lab Med 1990; 10:857.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/39\" class=\"nounderline abstract_t\">Gregg XT, Prchal JT. Erythropoietin receptor mutations and human disease. Semin Hematol 1997; 34:70.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/40\" class=\"nounderline abstract_t\">Arcasoy MO, Degar BA, Harris KW, Forget BG. Familial erythrocytosis associated with a short deletion in the erythropoietin receptor gene. Blood 1997; 89:4628.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/41\" class=\"nounderline abstract_t\">Kralovics R, Indrak K, Stopka T, et al. Two new EPO receptor mutations: truncated EPO receptors are most frequently associated with primary familial and congenital polycythemias. Blood 1997; 90:2057.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/42\" class=\"nounderline abstract_t\">Messinezy M, Westwood NB, El-Hemaidi I, et al. Serum erythropoietin values in erythrocytoses and in primary thrombocythaemia. Br J Haematol 2002; 117:47.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/43\" class=\"nounderline abstract_t\">Prchal JT, Sokol L. &quot;Benign erythrocytosis&quot; and other familial and congenital polycythemias. Eur J Haematol 1996; 57:263.</a></li><li class=\"breakAll\">Copelan EA, Balcerzac SP. Secondary polycythemia. In: Polycythemia Vera and the Myeloproliferative Disorders, Wasserman LR, Berk PD, Berlin NI (Eds), WB Saunders, Philadelphia 1995. p.195.</li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/45\" class=\"nounderline abstract_t\">Juvonen E, Ikkala E, Fyhrquist F, Ruutu T. Autosomal dominant erythrocytosis caused by increased sensitivity to erythropoietin. Blood 1991; 78:3066.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/46\" class=\"nounderline abstract_t\">Distelhorst CW, Wagner DS, Goldwasser E, Adamson JW. Autosomal Dominant familial erythrocytosis due to autonomous erythropoietin production. Blood 1981; 58:1155.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/47\" class=\"nounderline abstract_t\">Gaston RS, Julian BA, Curtis JJ. Posttransplant erythrocytosis: an enigma revisited. Am J Kidney Dis 1994; 24:1.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/48\" class=\"nounderline abstract_t\">Brox AG, Mangel J, Hanley JA, et al. Erythrocytosis after renal transplantation represents an abnormality of insulin-like growth factor-I and its binding proteins. Transplantation 1998; 66:1053.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/49\" class=\"nounderline abstract_t\">Chagnac A, Zevin D, Weinstein T, et al. Erythrocytosis associated with renal artery thrombosis in a patient with polycystic kidney disease on hemodialysis. Acta Haematol 1990; 84:40.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/50\" class=\"nounderline abstract_t\">Bacon BR, Rothman SA, Ricanati ES, Rashad FA. Renal artery stenosis with erythrocytosis after renal transplantation. Arch Intern Med 1980; 140:1206.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/51\" class=\"nounderline abstract_t\">Schramek A, Better OS, Adler O, et al. Hypertensive crisis, erythrocytosis, and uraemia due to renal-artery stenosis of kidney transplants. Lancet 1975; 1:70.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/52\" class=\"nounderline abstract_t\">Dr&eacute;nou B, Le Tulzo Y, Caulet-Maugendre S, et al. Pheochromocytoma and secondary erythrocytosis: role of tumour erythropoietin secretion. Nouv Rev Fr Hematol 1995; 37:197.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/53\" class=\"nounderline abstract_t\">Iliopoulos O, Levy AP, Jiang C, et al. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci U S A 1996; 93:10595.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/54\" class=\"nounderline abstract_t\">Wiesener MS, Seyfarth M, Warnecke C, et al. Paraneoplastic erythrocytosis associated with an inactivating point mutation of the von Hippel-Lindau gene in a renal cell carcinoma. Blood 2002; 99:3562.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/55\" class=\"nounderline abstract_t\">Yoshida M, Koshiyama M, Fujii H, Konishi M. Erythrocytosis and a fibroid. Lancet 1999; 354:216.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/56\" class=\"nounderline abstract_t\">Suzuki M, Takamizawa S, Nomaguchi K, et al. Erythropoietin synthesis by tumour tissues in a patient with uterine myoma and erythrocytosis. Br J Haematol 2001; 113:49.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/57\" class=\"nounderline abstract_t\">LevGur M, Levie MD. The myomatous erythrocytosis syndrome: a review. Obstet Gynecol 1995; 86:1026.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/58\" class=\"nounderline abstract_t\">Lanne JS, Dumortier J, Hervieu V, et al. Polycythemia and elevated serum erythropoietin associated with a liver haemangioma. Gastroenterol Clin Biol 2010; 34:629.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/59\" class=\"nounderline abstract_t\">Weisse AB, Moschos CB, Frank MJ, et al. Hemodynamic effects of staged hematocrit reduction in patients with stable cor pulmonale and severely elevated hematocrit levels. Am J Med 1975; 58:92.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/60\" class=\"nounderline abstract_t\">HARVEY RM, FERRER MI, COURNAND A. The treatment of chronic cor pulmonale. Circulation 1953; 7:932.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/61\" class=\"nounderline abstract_t\">AUCHINCLOSS JH Jr, DUGGAN JJ. Effects of venesection on pulmonary and cardiac function in patients with chronic pulmonary emphysema and secondary polycythemia. Am J Med 1957; 22:74.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia/abstract/62\" class=\"nounderline abstract_t\">Chetty KG, Brown SE, Light RW. Improved exercise tolerance of the polycythemic lung patient following phlebotomy. Am J Med 1983; 74:415.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 7075 Version 19.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H26\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">TERMINOLOGY</a><ul><li><a href=\"#H3\" id=\"outline-link-H3\">Relative polycythemia</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">Absolute polycythemia</a><ul><li><a href=\"#H5\" id=\"outline-link-H5\">- Primary polycythemia</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">- Secondary polycythemia</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">- Combined polycythemia</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">- Inapparent polycythemia</a></li></ul></li></ul></li><li><a href=\"#H9\" id=\"outline-link-H9\">PHYSIOLOGY OF ERYTHROPOIESIS</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">INITIAL EVALUATION</a><ul><li><a href=\"#H11\" id=\"outline-link-H11\">History</a></li><li><a href=\"#H12\" id=\"outline-link-H12\">Physical examination</a></li><li><a href=\"#H13\" id=\"outline-link-H13\">Laboratory testing</a></li></ul></li><li><a href=\"#H15\" id=\"outline-link-H15\">DOCUMENTATION AND DIAGNOSTIC APPROACH</a><ul><li><a href=\"#H16\" id=\"outline-link-H16\">Blood volume measurement</a></li><li><a href=\"#H17\" id=\"outline-link-H17\">Blood volume estimation</a></li><li><a href=\"#H18\" id=\"outline-link-H18\">Reduced plasma volume</a></li></ul></li><li><a href=\"#H19\" id=\"outline-link-H19\">FURTHER EVALUATION</a><ul><li><a href=\"#H20\" id=\"outline-link-H20\">Serum erythropoietin</a></li><li><a href=\"#H10215468\" id=\"outline-link-H10215468\">JAK2 mutation testing</a></li><li><a href=\"#H2597591\" id=\"outline-link-H2597591\">Bone marrow aspiration and biopsy</a></li></ul></li><li><a href=\"#H21\" id=\"outline-link-H21\">EVALUATION OF SECONDARY ERYTHROCYTOSIS</a><ul><li><a href=\"#H22\" id=\"outline-link-H22\">Congenital polycythemia</a></li><li><a href=\"#H23\" id=\"outline-link-H23\">Acquired secondary polycythemia</a><ul><li><a href=\"#H24\" id=\"outline-link-H24\">- Tumor polycythemia</a></li></ul></li><li><a href=\"#H25\" id=\"outline-link-H25\">Management</a><ul><li><a href=\"#H4659894\" id=\"outline-link-H4659894\">- Removal of the underlying cause</a></li><li><a href=\"#H4659900\" id=\"outline-link-H4659900\">- Limited phlebotomy</a></li></ul></li></ul></li><li><a href=\"#H26\" id=\"outline-link-H26\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"HEME/7075|ALG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"ALGORITHMS\">ALGORITHMS</a></div><ul><li><a href=\"image.htm?imageKey=HEME/102385\" class=\"graphic graphic_algorithm\">- Evaluation of suspected polycythemia vera</a></li></ul></li><li><div id=\"HEME/7075|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=HEME/53916\" class=\"graphic graphic_figure\">- Serum EPO and anemia</a></li><li><a href=\"image.htm?imageKey=HEME/81216\" class=\"graphic graphic_figure\">- Hemoglobin oxygen dissociation curve</a></li></ul></li><li><div id=\"HEME/7075|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=HEME/76036\" class=\"graphic graphic_table\">- Causes of erythrocytosis</a></li><li><a href=\"image.htm?imageKey=HEME/64238\" class=\"graphic graphic_table\">- Normal RBC parameters (adult)</a></li><li><a href=\"image.htm?imageKey=PEDS/57465\" class=\"graphic graphic_table\">- Normal hematologic values in children and adolescents</a></li><li><a href=\"image.htm?imageKey=HEME/110224\" class=\"graphic graphic_table\">- WHO diagnostic criteria polycythemia vera</a></li></ul></li></ul></div></div><div><h2>CALCULATORS</h2><div id=\"outlineCalculators\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=calculator-body-surface-area-mosteller-square-root-method\" title=\"calculator 1\" class=\"calc calc_professional\">Calculator: Body Surface Area (Mosteller, square root method)</a></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=approach-to-cyanosis-in-children\" class=\"medical medical_review\">Approach to cyanosis in children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=auscultation-of-cardiac-murmurs-in-adults\" class=\"medical medical_review\">Auscultation of cardiac murmurs in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=carbon-monoxide-poisoning\" class=\"medical medical_review\">Carbon monoxide poisoning</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-assessment-and-diagnosis-of-hypovolemia-dehydration-in-children\" class=\"medical medical_review\">Clinical assessment and diagnosis of hypovolemia (dehydration) in children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-features-and-diagnosis-of-primary-hepatocellular-carcinoma\" class=\"medical medical_review\">Clinical features and diagnosis of primary hepatocellular carcinoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-features-diagnosis-and-treatment-of-methemoglobinemia\" class=\"medical medical_review\">Clinical features, diagnosis, and treatment of methemoglobinemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome\" class=\"medical medical_review\">Clinical manifestations and diagnosis of hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-polycythemia-vera\" class=\"medical medical_review\">Clinical manifestations and diagnosis of polycythemia vera</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-the-thalassemias\" class=\"medical medical_review\">Clinical manifestations and diagnosis of the thalassemias</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-evaluation-and-staging-of-renal-cell-carcinoma\" class=\"medical medical_review\">Clinical manifestations, evaluation, and staging of renal cell carcinoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-presentation-and-diagnosis-of-pheochromocytoma\" class=\"medical medical_review\">Clinical presentation and diagnosis of pheochromocytoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-and-clinical-manifestations-of-cushings-syndrome\" class=\"medical medical_review\">Epidemiology and clinical manifestations of Cushing's syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=erythrocytosis-following-renal-transplantation\" class=\"medical medical_review\">Erythrocytosis following renal transplantation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=etiology-clinical-manifestations-and-diagnosis-of-volume-depletion-in-adults\" class=\"medical medical_review\">Etiology, clinical manifestations, and diagnosis of volume depletion in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=genetic-disorders-of-hemoglobin-oxygen-affinity\" class=\"medical medical_review\">Genetic disorders of hemoglobin oxygen affinity</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hemangioblastoma\" class=\"medical medical_review\">Hemangioblastoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-eisenmenger-syndrome\" class=\"medical medical_review\">Management of Eisenmenger syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=medical-management-of-cyanotic-congenital-heart-disease-in-adults\" class=\"medical medical_review\">Medical management of cyanotic congenital heart disease in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=molecular-biology-and-pathogenesis-of-von-hippel-lindau-disease\" class=\"medical medical_review\">Molecular biology and pathogenesis of von Hippel-Lindau disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera\" class=\"medical medical_review\">Molecular pathogenesis of congenital polycythemic disorders and polycythemia vera</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-cyanosis-in-the-newborn\" class=\"medical medical_review\">Overview of cyanosis in the newborn</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-hematopoietic-stem-cells\" class=\"medical medical_review\">Overview of hematopoietic stem cells</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-obstructive-sleep-apnea-in-adults\" class=\"medical medical_review\">Overview of obstructive sleep apnea in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-the-myeloproliferative-neoplasms\" class=\"medical medical_review\">Overview of the myeloproliferative neoplasms</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=oxygenation-and-mechanisms-of-hypoxemia\" class=\"medical medical_review\">Oxygenation and mechanisms of hypoxemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pulmonary-arteriovenous-malformations-epidemiology-etiology-and-pathology-in-adults\" class=\"medical medical_review\">Pulmonary arteriovenous malformations: Epidemiology, etiology, and pathology in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pulse-oximetry\" class=\"medical medical_review\">Pulse oximetry</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=regulation-of-erythropoiesis\" class=\"medical medical_review\">Regulation of erythropoiesis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=testosterone-treatment-of-male-hypogonadism\" class=\"medical medical_review\">Testosterone treatment of male hypogonadism</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=therapeutic-approach-to-adult-patients-with-pulmonary-arteriovenous-malformations\" class=\"medical medical_review\">Therapeutic approach to adult patients with pulmonary arteriovenous malformations</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=use-of-androgens-and-other-hormones-by-athletes\" class=\"medical medical_review\">Use of androgens and other hormones by athletes</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=uterine-leiomyomas-fibroids-epidemiology-clinical-features-diagnosis-and-natural-history\" class=\"medical medical_review\">Uterine leiomyomas (fibroids): Epidemiology, clinical features, diagnosis, and natural history</a></li></ul></div></div>","javascript":null}